2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

  
22 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04849065
(ClinicalTrials.gov)
May 1, 202115/4/2021Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral SclerosisClinical Trial in Phase II of Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis.ALS (Amyotrophic Lateral Sclerosis)Drug: MNC (Mononuclear cells);Drug: Placebo / SalineFundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaNULLNot yet recruiting18 Years70 YearsAll100Phase 2Spain
2NCT04681118
(ClinicalTrials.gov)
March 24, 202118/12/2020Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALSIntermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisBiological: NurOwn (MSC-NTF cells)Brainstorm-Cell TherapeuticsNULLNo longer available18 Years63 YearsAllUnited States
3NCT04651855
(ClinicalTrials.gov)
December 2, 202030/9/2020The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALSThe Evaluation of the Effect of Wharton's Jelly Mesenchymal Stem Cells (WJMSCs) on the Immune System of Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: Mesenchymal stem cells isolated from Wharton's jellyPolski Bank Komorek Macierzystych JSC (PBKM)National Center for Research and Development, PolandActive, not recruiting18 YearsN/AAll20Phase 1/Phase 2Poland
4EUCTR2018-004171-12-PL
(EUCTR)
22/07/202005/09/2019The evaluation of the effect of Wharton’s Jelly Mesenchymal Stem Cells (WJMSCs) on the immune system of patients with Amyotrophic Lateral Sclerosis (ALS)The evaluation of the effect of Wharton’s Jelly Mesenchymal Stem Cells (WJMSCs) on the immune system of patients with Amyotrophic Lateral Sclerosis (ALS) - ALSTEM Amyotrophic Lateral Sclerosis
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: FamC-1
INN or Proposed INN: WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELLS
Other descriptive name: WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELLS
Polski Bank Komórek Macierzystych JSC (PBKM)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 1;Phase 2Poland
5EUCTR2019-002302-46-ES
(EUCTR)
23/10/201909/08/2019Phase II clinical trial of intramuscular infusion of autologous bone marrow stem cells in patients with amyotrophic lateral sclerosisPhase II clinical trial of intramuscular infusion of autologous bone marrow stem cells in patients with amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: autologous adult bone marrow mononuclear cells (BM-MNC) unexpanded
INN or Proposed INN: autologous adult bone marrow mononuclear cells unexpanded
Other descriptive name: autologous adult bone marrow mononuclear cells unexpanded
Fundación para la Formación e Investigación Sanitarias de la Región de MurciaNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
100 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noSpain
6NCT03482050
(ClinicalTrials.gov)
April 12, 201814/3/2018A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)A Phase I/IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Theraputic Effects of Transplantation of Astrocytes Derived From Human Embryonic Stem Cells (hESC), in Patients With Amyotrophic Lateral Sclerosis (ALS)ALS (Amyotrophic Lateral Sclerosis)Biological: AstroRxKadimastemNULLCompleted18 Years70 YearsAll16Phase 1/Phase 2Israel
7NCT03280056
(ClinicalTrials.gov)
August 28, 201729/8/2017Safety and Efficacy of Repeated Administrations of NurOwn® in ALS PatientsA Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALSAmyotrophic Lateral Sclerosis (ALS)Biological: NurOwn® (MSC-NTF cells);Other: Placebo;Other: Bone Marrow aspirationBrainstorm-Cell TherapeuticsCalifornia Institute for Regenerative Medicine (CIRM)Completed18 Years60 YearsAll263Phase 3United States
8NCT03067857
(ClinicalTrials.gov)
September 201625/2/2017Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron DiseaseAutologous Purified Bone-Marrow-Derived Stem Cell Therapy for Motor Neuron DiseaseMotor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular Atrophy;Progressive Bulbar PalsiesBiological: Stem CellsStem Cells ArabiaNULLUnknown status24 Years70 YearsAll40Phase 1/Phase 2NULL
9NCT04821479
(ClinicalTrials.gov)
January 1, 201619/10/2020Repeated Mesenchymal Stem Cell Injections in ALSSafety and Clinical Effects of Repeated Intrathecal Injections of Autologous Mesenchymal Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisBiological: Mesenchymal stem cells (MSC)Hadassah Medical OrganizationNULLCompleted18 Years65 YearsAll20Phase 1/Phase 2NULL
10NCT02116634
(ClinicalTrials.gov)
May 20156/4/2014Mesenchymal Stem Cell Injection in Amyotrophic Lateral SclerosisPhase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) PatientsAmyotrophic Lateral SclerosisBiological: mesenchymal stem cellAlzahra Hospital, IranNULLWithdrawn18 Years60 YearsBoth0Phase 1/Phase 2Iran, Islamic Republic of
11NCT02987413
(ClinicalTrials.gov)
April 28, 20151/7/2016Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis PatientsSafety and Efficacy of Mesenchymal Stem Cells Escalated Application in Amyotrophic Lateral Sclerosis Patients: Study Design of a Phase I TrialMotor Neuron DiseaseBiological: Autologous Mesenchymal stem cells (MSCs)Hospital e Maternidade Dr. Christóvão da GamaIEP São Lucas - Instituto de Ensino e Pesquisa;Clinica Jordy Sinapse;TECHLIFE - Centro de Tecnologia CelularCompleted18 YearsN/AAll3Phase 1Brazil
12NCT02286011
(ClinicalTrials.gov)
November 201424/10/2014Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral SclerosisPhase I Clinical Trial on Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis.ALS (Amyotrophic Lateral Sclerosis)Biological: MNC (Mononuclear cells);Other: SalineRed de Terapia CelularSpanish National Health System;Hospital Universitario Virgen de la Arrixaca;Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia;Public Health Service, Murcia;Instituto Murciano de Investigación Biosanitaria Virgen de la ArrixacaActive, not recruiting18 Years70 YearsAll20Phase 1Spain
13NCT02492516
(ClinicalTrials.gov)
September 201424/6/2015Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALSEvaluation the Safety of Intravenous Injection of Adipose Derived Mesenchymal Stem Cell in Patients With ALSAmyotrophic Lateral SclerosisBiological: mesenchymal stem cellsRoyan InstituteNULLCompleted18 Years55 YearsAll19Phase 1Iran, Islamic Republic of
14EUCTR2011-004801-25-ES
(EUCTR)
16/07/201411/01/2013CLINICAL TRIAL ON THE USE OF BONE MARROW OWN PATIENT'S WITH AMYOTROPHIC LATERAL SCLEROSISA PHASE I/II CLINICAL TRIAL OF THE BONE MARROW'S AUTOLOGOUS STEM CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS amyotrophic lateral sclerosis
MedDRA version: 15.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: células troncales hematopoyéticas autólogas adultas extraidas de médula ósea
INN or Proposed INN: autologous bone marrow mononucleated cells
Other descriptive name: autologous bone marrow mononucleated cells
Fundación Sanitaria para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 1/2Spain
15NCT02017912
(ClinicalTrials.gov)
May 201417/12/2013Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALSA Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALSAmyotrophic Lateral Sclerosis (ALS)Biological: Autologous MSC-NTF cells;Biological: PlaceboBrainstorm-Cell TherapeuticsNULLCompleted18 Years75 YearsAll48Phase 2United States
16EUCTR2011-006254-85-ES
(EUCTR)
08/02/201309/08/2012Clinical trial to value the safety and efficacy of administration of stem cells derived from own patient for the treatment of Amyotrophic Lateral Sclerosis (ALS).Placebo controlled, randomized and triple blind multicentric phase I/II clinical trial to evaluate the safety, feasibility and valoration of efficacy trends of intravenous administration of three doses of autologous adipose derived autologous mesenchymal stem cells (CeTMAd) in moderate/severe ALS patients. Amyotrophic lateral sclerosis (ALS)
MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Células madre mesenquimales de tejido adiposo autólogo
INN or Proposed INN: NA
Other descriptive name: Células Mesenquimales de tejido adiposo
FUNDACIÓN PROGRESO Y SALUDNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 1/2Spain
17NCT01933321
(ClinicalTrials.gov)
September 201228/9/2012Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisBiological: Intrathecal autologous stem cellHospital Universitario Dr. Jose E. GonzalezNULLCompleted18 YearsN/ABoth14Phase 2/Phase 3Mexico
18NCT01609283
(ClinicalTrials.gov)
May 201218/5/2012A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral SclerosisA Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisBiological: autologous mesenchymal stem cellsMayo ClinicNULLCompleted18 YearsN/AAll27Phase 1United States
19EUCTR2011-000362-35-CZ
(EUCTR)
29/03/201205/04/2011Safety and Efficacy of Stem Cell Therapy of Motor Neuron Disease.A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis. - AMSC in ALS Amyotrophic lateral sclerosis
MedDRA version: 17.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Suspension of human autologous MSC 3P in 1,5 ml
Product Code: AMSC
INN or Proposed INN: Human autologous mesenchymal stem cells
Bioinova, s.r.o.NULLNot RecruitingFemale: yes
Male: yes
30Phase 2Czech Republic
20NCT01640067
(ClinicalTrials.gov)
December 20119/7/2012Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS)Intra-spinal Cord Delivery of Human Neural Stem Cells in ALS Patients: Proposal for a Phase I Study/ Trapianto Intramidollare di Cellule Staminali Neurali Umane Come Terapia Putativa Per la SLA: Proposta di un Trial Clinico di Fase IAmyotrophic Lateral SclerosisBiological: Human Neural Stem CellsAzienda Ospedaliera Santa Maria, Terni, ItalyAzienda Ospedaliero Universitaria Maggiore della Carita;Università di Padova ItalyCompleted20 Years75 YearsBoth18Phase 1Italy
21NCT01142856
(ClinicalTrials.gov)
June 201010/6/2010Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)A Single Patient Treatment Protocol for Autologous Mesenchymal Stem Cell Intraspinal Therapy in Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisBiological: autologous mesenchymal stem cellsMayo ClinicNULLCompleted18 YearsN/ABoth1Phase 1United States
22NCT01082653
(ClinicalTrials.gov)
March 20101/3/2010Safety/Efficacy Study for the Treatment of Amyotrophic Lateral SclerosisPhase I, Single Center, Prospective, Non-randomized, Open Label, Safety/Efficacy Study of the Infusion of Autologous Bone Marrow-derived Stem Cells, in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisBiological: autologous bone marrow-derived stem cellsTCA Cellular TherapyNULLSuspended18 Years80 YearsBoth6Phase 1United States